Reports Q4 revenue $979.6M, consensus $965.61M. Frank Laukien, Bruker’s (BRKR) president and CEO, commented: “The year 2024 was transformational for Bruker. We completed several strategic acquisitions to access very large addressable markets with strong secular tailwinds. In the process, we added key spatial biology, molecular diagnostics and lab automation platforms to our portfolio. For the fourth year in a row, Bruker has delivered well above-market organic and double-digit CER revenue growth. With approximately 70% cumulative revenue growth in the last four years, we have now achieved significant scale.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- BRKR Earnings this Week: How Will it Perform?
- Trump Trade: President to impose 25% tariffs on steel, aluminum imports
- Bruker price target lowered to $65 from $69 at Barclays
- Bruker price target lowered to $76 from $80 at BofA
- U.S. places new export controls on biotech equipment, Reuters reports